Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

BACKGROUND. Multiple myeloma is usually fatal due to serial relapses that become progressively refractory to therapy. CD19 is typically absent on the dominant multiple myeloma cell population but may be present on minor subsets with unique myeloma-propagating properties. To target myeloma-propagatin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Garfall, Alfred L., Stadtmauer, Edward A., Hwang, Wei-Ting, Lacey, Simon F., Melenhorst, Jan Joseph, Krevvata, Maria, Carroll, Martin P., Matsui, William H., Wang, Qiuju, Dhodapkar, Madhav V., Dhodapkar, Kavita, Das, Rituparna, Vogl, Dan T., Weiss, Brendan M., Cohen, Adam D., Mangan, Patricia A., Ayers, Emily C., Nunez-Cruz, Selene, Kulikovskaya, Irina, Davis, Megan M., Lamontagne, Anne, Dengel, Karen, Kerr, Naseem D.S., Young, Regina M., Siegel, Donald L., Levine, Bruce L., Milone, Michael C., Maus, Marcela V., June, Carl H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2018
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931130/
https://ncbi.nlm.nih.gov/pubmed/29669947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.120505
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados